Biotech

Spun out of DeepMind, Isomorphic Labs builds AI to design new medicines. Building on AlphaFold, its models predict how biological molecules interact and help scientists design potential drugs on computers. It combines machine learning with chemistry and biology, developing its own cancer and immune-disease drug candidates alongside pharmaceutical partnerships.

Recursion Pharmaceuticals is an AI drug-discovery company headquartered in Salt Lake City founded by Chris Gibson and others. It pairs automated cell imaging with machine learning to identify drug candidates (NASDAQ: RXRX).

Drug-discovery company applying machine learning to biology, founded by Daphne Koller.

Drug-discovery company applying generative AI to longevity and disease research.

Biotechnology company developing protein therapeutics through an integrated platform that combines machine learning, biological engineering, and automated experimentation.

AI-native drug-discovery company launched with over $1 billion in initial funding. Led by CEO Marc Tessier-Lavigne (former Genentech chief scientific officer) and co-founded by protein-design pioneer David Baker, combining generative models with wet-lab drug development.

AI biology company building foundation models for molecular structure prediction and drug-discovery workflows.

Combines generative models with proprietary biological data and laboratory validation to design new protein-based medicines, including antibodies against targets that conventional discovery methods struggle to address.